Related Experiment Video
Updated: Jun 30, 2026
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Value of BNP and tumour marker CA125 in patients with heart failure
Yang-Xin Chen1, Xiao-Qiao Wang, Chong-Feng Fang
1Department of Cardiology, the Second Affiliated Hospital of Sun Yat-sen University, Guangzhou Guangdong, People's Republic of China.
Insights
Carbohydrate antigen 125 (CA125) and B-type natriuretic peptide (BNP) are elevated in heart failure (HF) patients. Combined detection of BNP and CA125 improves HF diagnosis and treatment evaluation.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Heart failure (HF) diagnosis and management rely on clinical assessment and biomarkers.
- The role of tumour markers, such as carbohydrate antigen 125 (CA125), alongside established biomarkers like B-type natriuretic peptide (BNP) in HF requires further investigation.
Purpose of the Study:
- To investigate the association between B-type natriuretic peptide (BNP) and tumour markers, specifically CA125, in patients with heart failure (HF).
- To evaluate the diagnostic and therapeutic monitoring value of BNP and CA125 in HF patients.
Main Methods:
- A university hospital-based cross-over study involving 285 subjects.
- Participants included patients with HF, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and healthy controls.
- Measurements included BNP, CA125, and other tumour markers, alongside left ventricular ejection fraction.
Main Results:
- Both CA125 and BNP levels were significantly higher in HF patients compared to non-HF individuals and in severe HF versus mild HF.
- CA125 and BNP levels decreased significantly following aggressive treatment and clinical improvement.
- Left ventricular ejection fraction showed a positive correlation with both CA125 and BNP in left heart failure patients.
- Receiver-operator curve analysis indicated superior accuracy and positive predictive value for combined BNP and CA125 in diagnosing HF.
Conclusions:
- CA125 and BNP are significantly elevated in heart failure and closely correlate with cardiac function.
- These biomarkers effectively reflect the efficiency of short-term therapeutic interventions in HF.
- The combined detection of BNP and CA125 offers greater value for diagnosing HF and assessing treatment efficacy compared to individual markers.
Objective:
The objective was to study the association between B-type natriuretic peptide (BNP) and tumour markers and heart failure (HF) to evaluate the value of BNP and carbohydrate antigen 125 (CA125) in HF patients.
Design And Setting:
A university hospital-based cross-over study of 285 subjects (157 men and 128 women) in HF, chronic obstructive pulmonary disease (COPD), mild-mid pulmonary hypertension patients and control subjects.
Results:
CA125 and BNP were significantly higher in the HF group than in the non-HF group and in severe HF than in mild HF (P < 0.01). No changes were observed in other tumour markers. CA125 and BNP decreased obviously after clinical improvement by aggressive treatment (P < 0.01). Left ventricular ejection fraction correlated positively with CA125 (r = 0.789, P < 0.01) and BNP (r = 0.730, P < 0.01) in left heart failure patients, but not in other patients. BNP and CA125 had better accuracy and positive predictive value in diagnosing HF from the characteristic receiver-operator curve.
Conclusions:
CA125 and BNP are markedly elevated in heart failure and closely reflect heart function. They are better markers in evaluating the efficiency of short-term therapy. Detecting BNP combined with CA125 may be more valuable than only detecting BNP or CA125 for diagnosing HF and evaluating the efficiency of treatment.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Heart Failure VII: Nursing Interventions
01:22Heart Failure Drugs: β-Blockers
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
01:30Heart Failure IV: Classification and Diagnostic Evaluation